Cited by 633Clostridium difficile and Clostridium perfringens researchGastroesophageal reflux and treatmentsHelicobacter pylori-related gastroenterology studies

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Systematic Review of the Risk of Enteric Infection in Patients Taking Acid Suppression

Leonard, Jennifer, Marshall, John K., Moayyedi, Paul·2007·The American Journal of Gastroenterology

DOI 10.1111/j.1572-0241.2007.01275.x

Open this paper in CoChat — free account

Abstract

CONTEXT: Proton pump inhibitors (PPIs) and H(2) receptor antagonists (H(2)RAs) have become the mainstay of therapy in acid-related upper gastrointestinal disorders. There have been concerns raised about the possible association of PPIs with enteric infections. OBJECTIVE: We conducted a systematic review to evaluate any association between acid suppression and enteric infection. We also assessed differences between types of enteric infections and the type of acid suppression. DATA SOURCES: Electronic searches of MEDLINE (1966-2005), EMBASE (1988-2005), and CINAHL (1982-2005) were undertaken using a combination of subject headings and text words related to PPI therapy, H(2)RAs, and enteric infections. STUDY SELECTION: All observational studies were eligible, including cross-sectional, case control, and cohort studies that evaluated risk of enteric infection associated with antisecretory therapy. Eligibility assessment was made by two independent researchers. DATA EXTRACTION: Information on study design, patient population, type of acid suppression, type of infection, and outcomes was collected. The odds ratio (OR) of taking acid suppression therapy in cases and controls was calculated and results were synthesized using a random effects model (DerSimonian and Laird, Stats direct version 2.4.4). DATA SYNTHESIS: A total of 12 papers evaluating 2,948 patients with Clostridium difficile were included in the review. There was an increased risk of taking antisecretory therapy in those infected with C. difficile (pooled OR 1.94, 95% CI 1.37-2.75). There was significant heterogeneity between the studies (P= 0.0006) that was not explained by planned subgroup analysis. The association was greater for PPI use (OR 1.96, 95% CI 1.28-3.00) compared with H(2)RA use (OR 1.40, 95% CI 0.85-2.29). A total of six studies evaluated Salmonella, Campylobacter, and other enteric infections in 11,280 patients. There was an increased risk of taking acid suppression in those with enteric infections (OR 2.55, 95% CI 1.53-4.26). There was significant heterogeneity between the studies (P < 0.0001) that was not explained by subgroup analysis. The association was greater for PPI use (OR 3.33, 95% CI 1.84-6.02) compared with H(2)RA use (OR 2.03, 95% CI 1.05-3.92). CONCLUSION: There is an association between acid suppression and an increased risk of enteric infection. Further prospective studies on patients taking long-term acid suppression are needed to establish whether this association is causal.

Integrity signals

Registry

Crossref · 10.1111/j.1572-0241.2007.01275.x

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs
Concato, J., Shah, N., & Horwitz, R. I. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006223422507 · Cited by 3,563
Publication and related bias in meta-analysis
Sterne, J. A. C., Gavaghan, D., & Egger, M. (2000) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00242-0 · Cited by 2,282
A Predominantly Clonal Multi-Institutional Outbreak ofClostridium difficile–Associated Diarrhea with High Morbidity and Mortality
Loo, V. G., Poirier, L., Miller, M. A., Oughton, M., Libman, M., Michaud, S., Bourgault, A., Nguyen, T., Frenette, C. H., Kelly, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051639 · Cited by 1,962
Use of Gastric Acid–Suppressive Agents and the Risk of Community-Acquired Clostridium difficile –Associated Disease
Dial, S. (2005) · JAMA · doi:10.1001/jama.294.23.2989 · Cited by 954
Risk of Community-Acquired Pneumonia and Use of Gastric Acid–Suppressive Drugs
Laheij, R. J. F. (2004) · JAMA · doi:10.1001/jama.292.16.1955 · Cited by 879
A Large Outbreak ofClostridium difficile–Associated Disease with an Unexpected Proportion of Deaths and Colectomies at a Teaching Hospital Following Increased Fluoroquinolone Use
Muto, C. A., Pokrywka, M., Shutt, K. A., Mendelsohn, A. B., Nouri, K., Posey, K., Roberts, T. L., Croyle, K. S., Krystoflak, S., Patel-Brown, S., et al. (2005) · Infection Control and Hospital Epidemiology · doi:10.1086/502539 · Cited by 619
Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies
Dial, S. (2004) · Canadian Medical Association Journal · doi:10.1503/cmaj.1040876 · Cited by 577
Consensus Recommendations for Managing Patients with Nonvariceal Upper Gastrointestinal Bleeding
Barkun, A. N., Bardou, M., Marshall, J. K., & for the Nonvariceal Upper GI Bleeding Consensus Conference Group* (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-10-200311180-00012 · Cited by 540

Show all 46 references

Research works printed but not linked: 4

Laheij RJ, JAMA, 2004, 1955
10.1001/archinte.146.1.95 · DOI
Gillis C, 2006, Gastroenterol, 20, 191
Rostom A, 2002, Cochrane Database Syst Rev, 4

Sorted by citations

Items 101–200 of 631

Do we understand the pathophysiology of GERD after sleeve gastrectomy?
Felińska, E. A., Billeter, A. T., Nickel, F., Contin, P., Berlth, F., Chand, B., Grimminger, P., Mikami, D. J., SCHOPPMANN, S. F., & Müller-Stich, B. P. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14467 · Cited by 91
Gastrooesophageal reflux disease
Richter, J. E. (2007) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2007.03.003 · Cited by 86
The Safety of Appropriate Use of Over-the-Counter Proton Pump Inhibitors: An Evidence-Based Review and Delphi Consensus
Johnson, D. A., Katz, P. O., Armstrong, D., Cohen, H., Delaney, B. C., Howden, C. W., Katelaris, P., Tutuian, R. I., & Castell, D. O. (2017) · Drugs · doi:10.1007/s40265-017-0712-6 · Cited by 89
Are proton pump inhibitors really so dangerous?
Savarino, V., Dulbecco, P., & Savarino, E. V. (2016) · Digestive and Liver Disease · doi:10.1016/j.dld.2016.05.018 · Cited by 83
The regulation of gastric acid secretion – clinical perspectives
Waldum, H. L., Hauso, Ø., & Fossmark, R. (2013) · Acta Physiologica · doi:10.1111/apha.12208 · Cited by 83
Effects of Proton Pump Inhibitors on the Gastrointestinal Microbiota in Gastroesophageal Reflux Disease
Shi, Y., Cai, S., Tian, Y.-P., Zhao, H., Zhang, Y.-B., Chen, J., Ren, R.-R., Luo, X., Peng, L., Sun, G., et al. (2019) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2018.12.004 · Cited by 83
Proton Pump Inhibitors and Hospitalization with Hypomagnesemia: A Population-Based Case-Control Study
Zipursky, J. S., Macdonald, E. M., Hollands, S., Gomes, T., Mamdani, M., Paterson, J. M., Lathia, N., & Juurlink, D. N. (2014) · PLoS Medicine · doi:10.1371/journal.pmed.1001736 · Cited by 78
Gastric acidity inhibitors and the risk of intestinal infections
Canani, R. B., & Terrin, G. (2009) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e328333d781 · Cited by 76
Current Trends in the Management of Gastroesophageal Reflux Disease: A Review
Nwokediuko, S. C. (2012) · ISRN Gastroenterology · doi:10.5402/2012/391631 · Cited by 75
Prophylactic proton pump inhibition after atrial fibrillation ablation: is there any evidence?
Zellerhoff, S., Lenze, F., & Eckardt, L. (2011) · EP Europace · doi:10.1093/europace/eur139 · Cited by 74
Trends in Clostridium difficile Infection and Risk Factors for Hospital Acquisition of Clostridium difficile among Children with Cancer
de Blank, P. M. K., Zaoutis, T. E., Fisher, B. T., Troxel, A. B., Kim, J. Z., & Aplenc, R. (2013) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2013.01.062 · Cited by 74
Food-borne disease and climate change in the United Kingdom
LAKE, I. R. (2017) · Environmental Health · doi:10.1186/s12940-017-0327-0 · Cited by 74
American Society for Gastrointestinal Endoscopy guideline on the diagnosis and management of GERD: summary and recommendations
Desai, M., Ruan, W. H., Thosani, N. C., Amaris, M. A., Scott, J. S., Saeed, A., Dayyeh, B. K. A., Canto, M. I., Abidi, W. M., Alipour, O., et al. (2024) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2024.10.008 · Cited by 73
Use of proton pump inhibitors and subsequent risk of celiac disease
Lebwohl, B., Spechler, S. J., Wang, T. C., Green, P. H. R., & Ludvigsson, J. F. (2013) · Digestive and Liver Disease · doi:10.1016/j.dld.2013.08.128 · Cited by 71
Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications
McGinn, D., Godman, B., Lonsdale, J., Way, R., Wettermark, B., & Haycox, A. R. (2010) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/erp.09.73 · Cited by 69
The Clinician’s Guide to Proton Pump Inhibitor Related Adverse Events
Elias, E. D., & Targownik, L. E. (2019) · Drugs · doi:10.1007/s40265-019-01110-3 · Cited by 69
Potential adverse effects of proton pump inhibitors
Coté, G. A., & Howden, C. W. (2008) · Current Gastroenterology Reports · doi:10.1007/s11894-008-0045-4 · Cited by 69
Gastric Acid Suppression and Outcomes in Clostridium difficile Infection: A Population-Based Study
Khanna, S., Aronson, S., Kammer, P. P., Baddour, L. M., & Pardi, D. S. (2012) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2011.12.021 · Cited by 68
Emerging infections of the gastrointestinal tract
Schlenker, C., & Surawicz, C. M. (2009) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2008.11.014 · Cited by 68
Proton Pump Inhibitors: Risks and Rewards and Emerging Consequences to the Gut Microbiome
Singh, A., Cresci, G., & Kirby, D. F. (2018) · Nutrition in Clinical Practice · doi:10.1002/ncp.10181 · Cited by 69
Overuse of Acid Suppression Therapy in Hospitalized Patients
Gupta, R., Garg, P. K., Kottoor, R., Muñoz, J. C., Jamal, M. M., Lambiase, L. R., & Vega, K. J. (2010) · Southern Medical Journal · doi:10.1097/smj.0b013e3181ce0e7a · Cited by 67
Treatment of irritable bowel syndrome with probiotics: An etiopathogenic approach at last?
Jiménez, M. B. (2009) · Revista Española de Enfermedades Digestivas · doi:10.4321/s1130-01082009000800006 · Cited by 69
Side effects of long-term use of proton pump inhibitors: practical considerations
Castellana, C., Pecere, S., Furnari, M., Telese, A., Matteo, M. V., Haidry, R. J., & Eusebi, L. H. (2021) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.15997 · Cited by 66
The Many Manifestations of Gastroesophageal Reflux Disease: Presentation, Evaluation, and Treatment
Richter, J. E. (2007) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2007.07.014 · Cited by 66
Concomitant medications during immune checkpoint blockage in cancer patients: Novel insights in this emerging clinical scenario
Rossi, G., Pezzuto, A., Sini, C., Tuzi, A., Citarella, F., McCusker, M. G., Nigro, O., Tanda, E. T., & Russo, A. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.07.005 · Cited by 66
The Risk of Community-Acquired Enteric Infection in Proton Pump Inhibitor Therapy: Systematic Review and Meta-analysis
Hafiz, R. A., Wong, C. S., Paynter, S., David, M., & Peeters, G. M. E. E. (2018) · Annals of Pharmacotherapy · doi:10.1177/1060028018760569 · Cited by 69
Endotoxemia unrequired in the pathogenesis of pediatric nonalcoholic steatohepatitis
Yuan, J., Baker, S. S., Liu, W., Alkhouri, R. H., Baker, R. D., Xie, J., Ji, G., & Zhu, L. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12510 · Cited by 64
Mortality associated with proton pump inhibitors in cirrhotic patients with spontaneous bacterial peritonitis
Kwon, J. H., Koh, S., Kim, W. K., Jung, Y. J., Kim, J. W., Kim, B. G., Lee, K. L., Im, J. P., Kim, Y. J., Kim, J. S., et al. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12426 · Cited by 64
Prescribing Proton Pump Inhibitors
Vakil, N. B. (2012) · Drugs · doi:10.2165/11599320-000000000-00000 · Cited by 64
Potential proton pump inhibitor–related adverse effects
Perry, I. E., Sonu, I. S., Scarpignato, C., Akiyama, J., Hongo, M., & Vega, K. J. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14428 · Cited by 68
The Association between Histamine 2 Receptor Antagonist Use and Clostridium difficile Infection: A Systematic Review and Meta-analysis
Tleyjeh, I. M., Abdulhak, A. A. B., Riaz, M. A., Garbati, M. A., Al-Tannir, M. A., Alasmari, F. A., Alghamdi, M. A. A., Khan, A. R., Erwin, P. J., Sutton, A. J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056498 · Cited by 63
Is over-use of proton pump inhibitors fuelling the current epidemic of Clostridium difficile-associated diarrhoea?
Cunningham, R., & Dial, S. (2008) · Journal of Hospital Infection · doi:10.1016/j.jhin.2008.04.023 · Cited by 63
Probiotics for antibiotic-associated diarrhea: Do we have a verdict?
Issa, I. A., & Moucari, R. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i47.17788 · Cited by 65
Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications
Spakowicz, D. J., Hoyd, R., Muniak, M., Husain, M., Bassett, J. S., Wang, L., Tinoco, G., Patel, S. H., Burkart, J. T., Miah, A., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-06882-6 · Cited by 62
Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs
Godman, B., Sakshaug, S., Berg, C., Wettermark, B., & Haycox, A. R. (2011) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/erp.10.87 · Cited by 61
Risk of Community-Acquired Pneumonia in Veteran Patients to Whom Proton Pump Inhibitors Were Dispensed
Hermos, J. A., Young, M., Fonda, J. R., GAGNON, D. R., Fiore, L. D., & Lawler, E. V. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir767 · Cited by 61
Adverse Event Reporting for Proton Pump Inhibitor Therapy
Abramowitz, J. M., Thakkar, P., Isa, A., Truong, A., Park, C., & Rosenfeld, R. M. (2016) · Otolaryngology · doi:10.1177/0194599816648298 · Cited by 61
Inappropriate prescribing of proton pump inhibitors in hospitalized patients
Reid, M., Keniston, A., Heller, J. C., Miller, M. S., Medvedev, S., & Albert, R. K. (2011) · Journal of Hospital Medicine · doi:10.1002/jhm.1901 · Cited by 61
Gastroesophageal reflux symptoms do not correlate with objective pH testing after peroral endoscopic myotomy
Jones, E. L., Meara, M. P., Schwartz, J. S., Hazey, J. W., & Perry, K. A. (2015) · Surgical Endoscopy · doi:10.1007/s00464-015-4321-8 · Cited by 61
Microbiota in the stomach: New insights
Wu, W. M., Yang, Y., & Peng, L. H. (2013) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12116 · Cited by 59
Guideline for stress ulcer prophylaxis in the intensive care unit.
Madsen, K. R., Lorentzen, K., Clausen, N., Øberg, E., Kirkegaard, P. R. C., Maymann-Holler, N., & Møller, M. H. (2014) · PubMed · Cited by 60
Stress ulcer prophylaxis in the intensive care unit: is it indicated? A topical systematic review
Krag, M., Perner, A., Wetterslev, J., & Møller, M. H. (2013) · Acta Anaesthesiologica Scandinavica · doi:10.1111/aas.12099 · Cited by 61
Clinical update for the diagnosis and treatment ofClostridium difficileinfection
Oldfield, E. C. (2014) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v5.i1.1 · Cited by 63
Incidence of Campylobacter and Salmonella Infections Following First Prescription for PPI: A Cohort Study Using Routine Data
Brophy, S. T., Jones, K. H., Rahman, M. A., Zhou, S., John, A. M., Atkinson, M. D., Francis, N. A., Lyons, R. A., & Dunstan, F. (2013) · The American Journal of Gastroenterology · doi:10.1038/ajg.2013.30 · Cited by 58
The Positive Association between Proton Pump Inhibitors and Clostridium Difficile Infection
Tawam, D., Baladi, M., Jungsuwadee, P., Earl, G. L., & Han, J. (2021) · INNOVATIONS in pharmacy · doi:10.24926/iip.v12i1.3439 · Cited by 56
Optimal Management of Peptic Ulcer Disease in the Elderly
Pilotto, A., Franceschi, M., Maggi, S., Addante, F., & Sancarlo, D. (2010) · Drugs & Aging · doi:10.2165/11537380-000000000-00000 · Cited by 57
Public health relevance of drug–nutrition interactions
Péter, S., Navis, G. J., de Borst, M. H., von Schacky, C., van Orten-Luiten, A. C. B., Zhernakova, A., Witkamp, R. F., Janse, A., Weber, P., Bakker, S. J. L., et al. (2017) · European Journal of Nutrition · doi:10.1007/s00394-017-1510-3 · Cited by 68
Proton-pump inhibitors adverse effects: a review of the evidence and position statement by the Sociedad Española de Patología Digestiva
de la Coba Ortiz, C., Argüelles Arias, F., Martín de Argila de Prados, C., Júdez Gutiérrez, J., Linares Rodríguez, A., Ortega Alonso, A., Rodríguez de Santiago, E., Rodríguez-Téllez, M., Vera Mendoza, M. I., Aguilera Castro, L., et al. (2016) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2016.4232/2016 · Cited by 54
COVID-19-associated diarrhea
Megyeri, K., Dernovics, Á., Al-Luhaibi, Z. I. I., & Rosztoczy, A. I. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i23.3208 · Cited by 57
Proposed changes to management of lower respiratory tract infections in response to the Clostridium difficile epidemic
Chalmers, J. D., Al-Khairalla, M. Z. H., Short, P., Fardon, T. C., & Winter, J. H. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq038 · Cited by 54
Stress ulcer prophylaxis with a proton pump inhibitor versus placebo in critically ill patients (SUP-ICU trial): study protocol for a randomised controlled trial
the SUP-ICU investigators, Krag, M., Perner, A., Wetterslev, J., Wise, M. P., Borthwick, M., Bendel, S., Pelosi, P. P., Keus, F., Guttormsen, A. B., et al. (2016) · Trials · doi:10.1186/s13063-016-1331-3 · Cited by 53
Proton pump inhibitor side effects and drug interactions: Much ado about nothing?
Madanick, R. D. (2011) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.77a.10087 · Cited by 53
Inhibition of lysosomal enzyme activities by proton pump inhibitors
Liu, W., Baker, S. S., Trinidad, J. C., Burlingame, A. L., Baker, R. D., Forte, J. G., Virtuoso, L. P., Egilmez, N. K., & Zhu, L. (2013) · Journal of Gastroenterology · doi:10.1007/s00535-013-0774-5 · Cited by 53
Discontinuing Long-Term PPI Therapy: Why, With Whom, and How?
Targownik, L. E. (2018) · The American Journal of Gastroenterology · doi:10.1038/ajg.2018.29 · Cited by 56
Proton Pump Inhibitors
Schnoll‐Sussman, F. H., Niec, R. E., & Katz, P. O. (2020) · Gastrointestinal Endoscopy Clinics of North America · doi:10.1016/j.giec.2019.12.005 · Cited by 55
Proton Pump Inhibitors Interfere With Zinc Absorption and Zinc Body Stores
Farrell (2011) · Gastroenterology Research · doi:10.4021/gr379w · Cited by 51
Discontinuation of long-term proton pump inhibitor therapy in primary care patients: a randomized placebo-controlled trial in patients with symptom relapse
Reimer, C., & Bytzer, P. M. (2010) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e32833d56d1 · Cited by 50
Prevalence and clinical course of Clostridium difficile infection in a tertiary-care hospital: a retrospective analysis
Ingle, M., Deshmukh, A. M., Desai, D., Abraham, P., Joshi, A. G., Rodrigues, C. S., & Mankeshwar, R. (2011) · Indian Journal of Gastroenterology · doi:10.1007/s12664-011-0097-5 · Cited by 50
Association Between Proton Pump Inhibitor Use and Spontaneous Bacterial Peritonitis in Cirrhotic Patients with Ascites
Ratelle, M., Perreault, S., Villeneuve, J., & Tremblay, L. (2014) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2014/751921 · Cited by 49
A Benefit–Risk Assessment of the Use of Proton Pump Inhibitors in the Elderly
Masclee, G. M. C., Sturkenboom, M., & Kuipers, E. J. (2014) · Drugs & Aging · doi:10.1007/s40266-014-0166-4 · Cited by 52
Widespread use of gastric acid inhibitors in infants: Are they needed? Are they safe?
Safe, M., Chan, W. H., Leach, S. T., SUTTON, L. J., Lui, K., & Krishnan, U. (2016) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v7.i4.531 · Cited by 49
Clostridium difficileinfection in children: a comprehensive review
Pant, C., Deshpande, A., Altaf, M. A., Minocha, A., & Sferra, T. J. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.803058 · Cited by 48
Use of proton-pump inhibitors and their associated risks among frail elderly nursing home residents
Teramura-Grönblad, M., Hosia‐Randell, H., Muurinen, S., & Pitkälä, K. H. (2010) · Scandinavian Journal of Primary Health Care · doi:10.3109/02813432.2010.493315 · Cited by 48
Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future direction
Coma, A. V., Zara, C., Godman, B., Agustí, A., Diogène, E., Wettermark, B., & Haycox, A. R. (2009) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/erp.09.58 · Cited by 47
Interplays between drugs and the gut microbiome
Wan, Y., & Zuo, T. (2022) · Gastroenterology report · doi:10.1093/gastro/goac009 · Cited by 47
Potential harms of proton pump inhibitor therapy: rare adverse effects of commonly used drugs
Benmassaoud, A., McDonald, E. G., & Lee, T. C. (2015) · Canadian Medical Association Journal · doi:10.1503/cmaj.150570 · Cited by 46
Are there risks associated with empiric acid suppression treatment of infants and children suspected of having gastroesophageal reflux disease?
Chung, E., & Yardley, J. (2013) · Hospital Pediatrics · doi:10.1542/hpeds.2012-0077 · Cited by 45
Clinical Implications of Emerging Data on the Safety of Proton Pump Inhibitors
Schnoll‐Sussman, F. H., & Katz, P. O. (2017) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-017-0115-5 · Cited by 47
Stress Prophylaxis in Intensive Care Unit Patients and the Role of Enteral Nutrition
Hurt, R. T., Frazier, T. H., McClave, S. A., Crittenden, N. E., Kulisek, C., Saad, M., & Franklin, G. A. (2012) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/0148607112436978 · Cited by 43
Common Drug Side Effects and Drug-Drug Interactions in Elderly Adults in Primary Care
Merel, S. E., & Paauw, D. S. (2017) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14870 · Cited by 48
Proton Pump Inhibitor Use and Risk of Developing Alzheimer’s Disease or Vascular Dementia: A Case–Control Analysis
Imfeld, P., Bodmer, M., Jick, S. S., & Meier, C. R. (2018) · Drug Safety · doi:10.1007/s40264-018-0704-9 · Cited by 44
Retrospective Analysis to Investigate the Effect of Concomitant Use of Gastric Acid–Suppressing Drugs on the Efficacy and Safety of Pancrelipase/Pancreatin (CREON®) in Patients With Pancreatic Exocrine Insufficiency
Sander‐Struckmeier, S., Beckmann, K., Solingen, G. J.-V., & Pollack, P. (2013) · Pancreas · doi:10.1097/mpa.0b013e31828784ef · Cited by 44
AGA Clinical Practice Guideline on Surveillance of Barrett’s Esophagus
Wani, S., Zhou, M. J., Sawas, T., Rubenstein, J. H., Eluri, S., Leiman, D. A., Sultan, S., Singh, S., Inadomi, J. M., Thrift, A. P., et al. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.09.012 · Cited by 45
Acid Inhibition and Infections Outside the Gastrointestinal Tract
Vakil, N. B. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.47 · Cited by 43
Proton pump inhibitors: are they overutilised in clinical practice and do they pose significant risk?
Heidelbaugh, J. J., Metz, D. C., & Yang, Y. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2012.02921.x · Cited by 42
Clostridium difficile infection
Stanley, J. D., Bartlett, J. G., Dart, B. W., & Ashcraft, J. (2013) · Current Problems in Surgery · doi:10.1067/j.cpsurg.2013.02.004 · Cited by 42
Stress ulcer prophylaxis in critically ill patients: review of the evidence
Alhazzani, W. A., Alshahrani, M. S. S., Moayyedi, P., & Jaeschke, R. (2012) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.1173 · Cited by 42
Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency: influence and future directions
Marković‐Peković, V., Škrbić, R., Godman, B., & Gustafsson, L. L. (2012) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/erp.12.48 · Cited by 41
Reducing adverse effects of proton pump inhibitors.
Ament, P. W., Dicola, D. B., & James, M. E. (2012) · PubMed · Cited by 41
Nonlinear machine learning pattern recognition and bacteria-metabolite multilayer network analysis of perturbed gastric microbiome
Durán, C., Ciucci, S., Palladini, A., Ijaz, U. Z., Zippo, A. G., Sterbini, F. P., Masucci, L., Cammarota, G., Ianiro, G., Spuul, P., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22135-x · Cited by 43
Antimicrobial stewardship programs in adult intensive care units in Latin America: Implementation, assessments, and impact on outcomes
Quiros, R. E., Bardossy, A. C., Angeleri, P., Zurita, J., Espinoza, W. R. A., Carneiro, M., Guerra, S., Medina, J., Luquerna, X. C., Guerra, A., et al. (2021) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2021.80 · Cited by 41
Is There a Dark Side to Long-term Proton Pump Inhibitor Therapy?
Nealis, T. B., & Howden, C. W. (2008) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31817149bf · Cited by 41
Cost-Effectiveness of Histamine Receptor-2 Antagonist Versus Proton Pump Inhibitor for Stress Ulcer Prophylaxis in Critically Ill Patients*
MacLaren, R., & Campbell, J. (2013) · Critical Care Medicine · doi:10.1097/ccm.0000000000000032 · Cited by 40
Latest insights into the hot question of proton pump inhibitor safety – a narrative review
Savarino, V., Marabotto, E., Furnari, M., Zingone, F., Zentilin, P., & Savarino, E. V. (2020) · Digestive and Liver Disease · doi:10.1016/j.dld.2020.04.020 · Cited by 40
A Multidisciplinary Approach to Incorporate Bedside Nurses into Antimicrobial Stewardship and Infection Prevention
Ha, D. R., Forte, M. B., Olans, R. D., OYong, K., Olans, R. N., Gluckstein, D. P., Kullar, R., Desai, M., Catipon, N., Ancheta, V., et al. (2019) · The Joint Commission Journal on Quality and Patient Safety · doi:10.1016/j.jcjq.2019.03.003 · Cited by 39
Oral–Gut Microbiome Axis in Gastrointestinal Disease and Cancer
Park, S.-Y., Hwang, B.-O., Lim, M., Ok, S. H., Lee, S., Chun, K., Park, K.-K., Hu, Y., Chung, W., & Song, N. (2021) · Cancers · doi:10.3390/cancers13071748 · Cited by 44
Japanese Clinical Practice Guidelines for Management of Clostridioides (Clostridium) difficile infection
Kunishima, H., Ohge, H., Suzuki, H., Nakamura, A., Matsumoto, K., Mikamo, H., Mori, N., Morinaga, Y., Yanagihara, K., Yamagishi, Y., et al. (2022) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2021.12.011 · Cited by 39
Inappropriate continuation of stress ulcer prophylaxis beyond the intensive care setting
Farley, K. J., Barned, K. L., & Crozier, T. M. E. (2013) · Critical Care and Resuscitation · doi:10.1016/s1441-2772(23)01783-0 · Cited by 41
The Safety of Drugs Used in Acid-related Disorders and Functional Gastrointestinal Disorders
Parikh, N., & Howden, C. (2010) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2010.08.009 · Cited by 40
Clostridium difficile infection in patients with liver disease: a review
Trifan, A. V., Stoica, O. C., Stanciu, C., Cojocariu, C., Sîngeap, A.-M., Gîrleanu, I., & Miftode, E. G. (2015) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-015-2501-z · Cited by 38
Proton Pump Inhibitor use in Hospitalized Patients: Is Overutilization Becoming a Problem?
Durand, C. R., Willett, K. C., & Desilets, A. R. (2012) · Clinical Medicine Insights Gastroenterology · doi:10.4137/cgast.s9588 · Cited by 44
Ten Common Statistical Errors and How to Avoid Them
Zinsmeister, A. R., & Connor, J. T. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01590.x · Cited by 38
Prescribing patterns of proton pump inhibitors in older hospitalized patients in a S cottish health board
Jarchow-MacDonald, A., & Mangoni, A. A. (2013) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.12047 · Cited by 38
Proton Pump Inhibitors in Gastroesophageal Reflux Disease: Friend or Foe
Gyawali, C. P. (2017) · Current Gastroenterology Reports · doi:10.1007/s11894-017-0586-5 · Cited by 38
A national case-control study of risk factors for listeriosis in Australia
Dalton, C. B., Merritt, T. D., UNICOMB, L. E., Kirk, M., Stafford, R. J., Lalor, K., & the OzFoodNet Working Group (2010) · Epidemiology and Infection · doi:10.1017/s0950268810000944 · Cited by 38
Nizatidine Improves Clinical Symptoms and Gastric Emptying in Patients with Functional Dyspepsia Accompanied by Impaired Gastric Emptying
Futagami, S., Shimpuku, M., Song, J. M., Kodaka, Y., Yamawaki, H., Nagoya, H., Shindo, T., Kawagoe, T., Horie, A., Gudis, K., et al. (2012) · Digestion · doi:10.1159/000339111 · Cited by 37
Acid‐suppression medications and bacterial gastroenteritis: a population‐based cohort study
Wei, L., Ratnayake, L., Phillips, G., McGuigan, C. C., Morant, S. V., Flynn, R., Mackenzie, I. S., & MacDonald, T. M. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13205 · Cited by 37
Proton pump inhibitors and dementia risk: Evidence from a cohort study using linked routinely collected national health data in Wales, UK
Cooksey, R., Kennedy, J. I., Dennis, M., Escott‐Price, V., Lyons, R. A., Seaborne, M., & Brophy, S. T. (2020) · PLoS ONE · doi:10.1371/journal.pone.0237676 · Cited by 37
Adverse Risks Associated With Proton Pump Inhibitors: A Systematic Review.
Heidelbaugh, J. J., Goldberg, K. L., & Inadomi, J. M. (2009) · PubMed Central · Cited by 36
Side Effects and Complications of Proton Pump Inhibitors: A Pediatric Perspective
Stark, C. M., & Nylund, C. M. (2015) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2015.08.064 · Cited by 36

Authors: Leonard, J., Marshall, J. K., & Moayyedi, P.
Affiliations: McMaster University (CA)
ORCID: Marshall, John K.
Moayyedi, Paul
Venue: The American Journal of Gastroenterology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2007-09
Volume: 102
Issue: 9
Pages: 2047-2056
ISSN: 0002-9270 (ISSN-L)
1572-0241
DOI: 10.1111/j.1572-0241.2007.01275.x
OpenAlex: W2114271048
Cited by: 633
References: 46
Citations by year: 2026: 6 · 2025: 17 · 2024: 22 · 2023: 24 · 2022: 32 · 2021: 35 · 2020: 39 · 2019: 29 · 2018: 35 · 2017: 41 · 2016: 30 · 2015: 28 · 2014: 30 · 2013: 63 · 2012: 55
FWCI: 3.82
Type: journal article
Language: en
Open access: closed
Locations: The American Journal of Gastroenterology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
Health Sciences › Medicine › Gastroenterology › Gastroesophageal reflux and treatments
Health Sciences › Medicine › Gastroenterology › Helicobacter pylori-related gastroenterology studies
Keywords: acid suppression, proton pump inhibitors, H2 receptor antagonists, gastrointestinal infections, Clostridium difficile infection, Salmonella, Campylobacter, Clostridium difficile-associated diarrhea, antisecretory therapy, infection risk, drug safety, Helicobacter pylori, Helicobacter heilmannii
MeSH terms: Bacterial Infections, Gastric Acid, Gastrointestinal Diseases, Histamine H2 Antagonists, Humans, Risk Factors, Proton Pump Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Systematic Review of the Risk of Enteric Infection in Patients Taking Acid Suppression

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks